Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell disease
J Lewis, GMT Guilcher… - European Journal of …, 2024 - Wiley Online Library
Hydroxyurea (HU) is the most common drug therapy for sickle cell disease (SCD). The
clinical benefits of HU derive from its upregulation of fetal hemoglobin (HbF), which reduces …
clinical benefits of HU derive from its upregulation of fetal hemoglobin (HbF), which reduces …